ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-18 11:07:32,2024-07-18T11:07:32-04:00,2024-07-18,Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2304507/earnings-preview-abbvie-abbv-q2-earnings-expected-to-decline?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2304507,https://images.financialmodelingprep.com/news/earnings-preview-abbvie-abbv-q2-earnings-expected-to-decline-20240718.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-19 14:36:58,2024-07-19T14:36:58-04:00,2024-07-19,AbbVie: Why I Sold My Shares At $175,"We recently sold our ABBV shares at $175. The stock has reached our target valuation at this price. More fundamentally, we think the market has corrected its overreaction to the Humira patent cliff by now.",seekingalpha.com,https://seekingalpha.com/article/4705168-abbvie-why-i-sold-my-shares-at-175,https://images.financialmodelingprep.com/news/abbvie-why-i-sold-my-shares-at-175-20240719.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-19 18:51:55,2024-07-19T18:51:55-04:00,2024-07-19,AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts,"AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.",zacks.com,https://www.zacks.com/stock/news/2305599/abbvie-abbv-rises-as-market-takes-a-dip-key-facts?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2305599,https://images.financialmodelingprep.com/news/abbvie-abbv-rises-as-market-takes-a-dip-key-facts-20240719.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-20 09:00:00,2024-07-20T09:00:00-04:00,2024-07-20,7 Investments To Buy And Hold For Next 10 Years,"We present a diversified yet simple portfolio of 6 stocks and one ETF with nearly 4% dividend yield. The portfolio has been designed for retirees and income investors whose needs are generally met with a 4% income yield. This portfolio is not meant for high-income investors. We believe the portfolio presented will likely provide market-matching total returns and at least 6% dividend growth over the long term, handily beating inflation.",seekingalpha.com,https://seekingalpha.com/article/4704484-7-investments-to-buy-and-hold-for-next-10-years,https://images.financialmodelingprep.com/news/7-investments-to-buy-and-hold-for-next-10-20240720.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-21 10:30:00,2024-07-21T10:30:00-04:00,2024-07-21,10 Best Dividend Growth Stocks to Buy and Hold Forever,"These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.",fool.com,https://www.fool.com/investing/2024/07/21/10-best-dividend-growth-stocks-to-buy-and-hold-for/,https://images.financialmodelingprep.com/news/10-best-dividend-growth-stocks-to-buy-and-hold-20240721.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-22 10:41:00,2024-07-22T10:41:00-04:00,2024-07-22,"AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?","AbbVie's lead drug, Humira, lost patent-protected market exclusivity in 2023, but sales have been relatively resilient to new competition. Despite losing billions in Humira revenue, total sales are still on the rise.",fool.com,https://www.fool.com/investing/2024/07/22/abbvie-could-soar-24-according-to-a-wall-street-an/,https://images.financialmodelingprep.com/news/abbvie-could-soar-24-according-to-a-wall-street-20240722.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-22 10:51:16,2024-07-22T10:51:16-04:00,2024-07-22,AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?,Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.,zacks.com,https://www.zacks.com/stock/news/2306144/abbvie-abbv-stock-before-q2-earnings-to-buy-or-not-to-buy?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2306144,https://images.financialmodelingprep.com/news/abbvie-abbv-stock-before-q2-earnings-to-buy-or-20240722.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-23 07:00:00,2024-07-23T07:00:00-04:00,2024-07-23,"Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor","BOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the advancement of lead candidates for further optimization in an AbbVie partnered program targeting a key transcription factor for cancer cell survival, triggering an accompanying milestone payment.",globenewswire.com,https://www.globenewswire.com/news-release/2024/07/23/2917078/0/en/Frontier-Medicines-Announces-Milestone-Payment-in-AbbVie-Partnership-Following-Advancement-of-Lead-Candidates-Targeting-a-Historically-Undruggable-Transcription-Factor.html,https://images.financialmodelingprep.com/news/frontier-medicines-announces-milestone-payment-in-abbvie-partnership-following-20240723.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-23 12:15:23,2024-07-23T12:15:23-04:00,2024-07-23,Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?,"Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.",zacks.com,https://www.zacks.com/stock/news/2307083/will-these-5-medical-stocks-surpass-q2-earnings-forecasts?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2307083,https://images.financialmodelingprep.com/news/will-these-5-medical-stocks-surpass-q2-earnings-forecasts-20240723.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-24 08:10:00,2024-07-24T08:10:00-04:00,2024-07-24,My Dividend Stock Portfolio: New June Dividend Record - 101 Holdings With 22 Buys,"Investment activity remained high in June, focusing on BDCs aiming to increase dividend income by at least $100 each month. Adjusted dividend income in June is up 27% Y/Y and 5% vs the previous quarter. Main portfolio picks included Ares Capital, Hercules Capital, Goldman Sachs BDC, and MidCap Financial Investment Corporation.",seekingalpha.com,https://seekingalpha.com/article/4706053-my-dividend-stock-portfolio-new-june-dividend-record-101-holdings-with-22-buys,https://images.financialmodelingprep.com/news/my-dividend-stock-portfolio-new-june-dividend-record-101-20240724.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-24 16:18:53,2024-07-24T16:18:53-04:00,2024-07-24,7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio,"Arguably, there's never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation.",investorplace.com,https://investorplace.com/2024/07/7-trustworthy-dividend-stocks-to-steadily-build-your-portfolio/,https://images.financialmodelingprep.com/news/7-trustworthy-dividend-stocks-to-steadily-build-your-portfolio-20240724.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 07:36:00,2024-07-25T07:36:00-04:00,2024-07-25,AbbVie Reports Second-Quarter 2024 Financial Results,"Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones Expense    Delivers Second-Quarter Net Revenues of $14.462 Billion, an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational Basis    Second -Quarter Global Net Revenues from the Immunology Portfolio Were $6.971 Billion, an Increase of 2.3 Percent on a Reported Basis, or 3.5 Percent on an Operational Basis; Global Humira Net Revenues Were $2.814 Billion; Global Skyrizi Net Revenues Were $2.727 Billion; Global Rinvoq Net Revenues Were $1.430 Billion   Second -Quarter Global Net Revenues from the Oncology Portfolio Were $1.634 Billion, an Increase of 10.5 Percent on a Reported Basis, or 12.2 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $833 Million; Global Venclexta Net Revenues Were $637 Million   Second -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.162 Billion, an Increase of 14.7 Percent on a Reported Basis, or 15.2 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $814 Million; Global Vraylar Net Revenues Were $774 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $381 Million   Second -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.390 Billion, an Increase of 0.5 Percent on a Reported Basis, or 2.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $729 Million; Global Juvederm Net Revenues Were $343 Million   Raises 2024 Adjusted Diluted EPS Guidance Range from $10.61 - $10.81 to $10.71 - $10.91, which Includes an Unfavorable Impact of $0.60 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2024 NORTH CHICAGO, Ill. , July 25, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2024.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2024-financial-results-302205992.html,https://images.financialmodelingprep.com/news/abbvie-reports-secondquarter-2024-financial-results-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 07:39:39,2024-07-25T07:39:39-04:00,2024-07-25,AbbVie lifts annual profit forecast on strong immunology drug sales,"AbbVie raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-strong-immunology-drug-sales-2024-07-25/,https://images.financialmodelingprep.com/news/abbvie-lifts-annual-profit-forecast-on-strong-immunology-drug-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 07:45:00,2024-07-25T07:45:00-04:00,2024-07-25,Is AbbVie the Best Dividend Stock for You?,"AbbVie lost its CEO last year even as its most important drug experienced a patent cliff. However, the company's business remains robust thanks to a deep lineup and rich pipeline.",fool.com,https://www.fool.com/investing/2024/07/25/is-abbvie-the-best-dividend-stock-for-you/,https://images.financialmodelingprep.com/news/is-abbvie-the-best-dividend-stock-for-you-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 08:46:00,2024-07-25T08:46:00-04:00,2024-07-25,AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.,AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.,barrons.com,https://www.barrons.com/articles/abbvie-earnings-stock-price-08bc6a8b,https://images.financialmodelingprep.com/news/abbvie-stock-is-rising-on-strong-earnings-ceo-cites-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 09:47:11,2024-07-25T09:47:11-04:00,2024-07-25,AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates,"AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2308650/abbvie-abbv-tops-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2308650,https://images.financialmodelingprep.com/news/abbvie-abbv-tops-q2-earnings-and-revenue-estimates-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 10:30:44,2024-07-25T10:30:44-04:00,2024-07-25,Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?,"The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.",zacks.com,https://www.zacks.com/stock/news/2308830/wall-street-analysts-see-abbvie-abbv-as-a-buy-should-you-invest?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|average_broker_rating-2308830,https://images.financialmodelingprep.com/news/wall-street-analysts-see-abbvie-abbv-as-a-buy-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 10:31:57,2024-07-25T10:31:57-04:00,2024-07-25,AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today,AbbVie (NYSE: ABBV ) stock is the top trending ticker on Yahoo Finance on Thursday as investors are pumped up about news from the pharmaceutical company's latest earnings report. AbbVie started its earnings report for Q2 with adjusted EPS of $2.65.,investorplace.com,https://investorplace.com/2024/07/abbvie-stock-news-why-abbv-is-the-top-trending-ticker-today/,https://images.financialmodelingprep.com/news/abbvie-stock-news-why-abbv-is-the-top-trending-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 10:35:46,2024-07-25T10:35:46-04:00,2024-07-25,AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates,"While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2308800/abbvie-abbv-q2-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2308800,https://images.financialmodelingprep.com/news/abbvie-abbv-q2-earnings-taking-a-look-at-key-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 11:26:14,2024-07-25T11:26:14-04:00,2024-07-25,"AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View",AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.,zacks.com,https://www.zacks.com/stock/news/2309203/abbvie-abbv-beats-on-q2-earnings-sales-ups-24-eps-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2309203,https://images.financialmodelingprep.com/news/abbvie-abbv-beats-on-q2-earnings-sales-ups-24-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 13:31:46,2024-07-25T13:31:46-04:00,2024-07-25,AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio,AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in Humira sales.,investopedia.com,https://www.investopedia.com/abbvie-stock-hits-record-high-on-demand-for-non-humira-portfolio-8683570,https://images.financialmodelingprep.com/news/abbvie-stock-hits-record-high-on-demand-for-nonhumira-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-25 16:25:02,2024-07-25T16:25:02-04:00,2024-07-25,Why AbbVie Stock Was Cruising Higher on Thursday,"The pharmaceutical sector mainstay posted a mixed second quarter. It topped analyst expectations for revenue and missed those for profitability, but investors were more focused on the future.",fool.com,https://www.fool.com/investing/2024/07/25/why-abbvie-stock-was-cruising-higher-on-thursday/,https://images.financialmodelingprep.com/news/why-abbvie-stock-was-cruising-higher-on-thursday-20240725.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-26 02:00:00,2024-07-26T02:00:00-04:00,2024-07-26,AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis,"The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE induction trial1 and COMMAND maintenance trial2 In both trials, SKYRIZI achieved the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including mucosal healing** and histologic endoscopic mucosal healing †, 1 , 2 NORTH CHICAGO, Ill. , July 26, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved SKYRIZI® (risankizumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.3 ""Ulcerative colitis is a chronic, unpredictable and sometimes debilitating disease, and people living with the condition need sustained symptom relief,"" said Edouard Louis, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-302207241.html,https://images.financialmodelingprep.com/news/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-20240726.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-26 14:54:10,2024-07-26T14:54:10-04:00,2024-07-26,"AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations","On Thursday, AbbVie Inc.  ABBV reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.",benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992204/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growt,https://images.financialmodelingprep.com/news/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-20240726.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-28 09:10:21,2024-07-28T09:10:21-04:00,2024-07-28,AbbVie: Q2 Earnings Validate Bullish Case,"AbbVie's recent Q2 earnings release was robust, validating my initial bullish thesis, which has aged well as the stock has outperformed the broader market since mid-April. The Q2 earnings release strengthened my bullish stance due to the robust performance across all business lines, solid operating leverage, and immense momentum in AbbVie's flagship products. According to my valuation analysis, ABBV stock is still around 35% undervalued.",seekingalpha.com,https://seekingalpha.com/article/4707523-abbvie-q2-earnings-validate-bullish-case,https://images.financialmodelingprep.com/news/abbvie-q2-earnings-validate-bullish-case-20240728.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-29 09:50:18,2024-07-29T09:50:18-04:00,2024-07-29,3 High-Yield Dividend Stocks That Are Looking Super Hot,"High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.",investorplace.com,https://investorplace.com/2024/07/3-high-yield-dividend-stocks-that-are-looking-super-hot/,https://images.financialmodelingprep.com/news/3-highyield-dividend-stocks-that-are-looking-super-hot-20240729.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-29 12:19:39,2024-07-29T12:19:39-04:00,2024-07-29,AbbVie: Growth Is Still A Better Choice,"On July 25, AbbVie released its Q2 2024 financial results, which surprised me with surging sales of its immunology and neuroscience franchises. So, Rinvoq's sales amounted to $1.43 billion for the three months ended June 30, 2024, an increase of 55.8% year-on-year. On the other hand, sales of Elahere, a targeted anticancer drug, amounted to $128 million in the second quarter of 2024, increasing by 65.4% year-on-year.",seekingalpha.com,https://seekingalpha.com/article/4707698-abbvie-growth-is-still-a-better-choice,https://images.financialmodelingprep.com/news/abbvie-growth-is-still-a-better-choice-20240729.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-29 13:37:34,2024-07-29T13:37:34-04:00,2024-07-29,Pharma companies less concerned after hearing from US on negotiated prices for Medicare,Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-companies-less-concerned-after-hearing-us-negotiated-prices-medicare-2024-07-29/,https://images.financialmodelingprep.com/news/pharma-companies-less-concerned-after-hearing-from-us-on-20240729.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-30 08:00:00,2024-07-30T08:00:00-04:00,2024-07-30,Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day,"Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024 Members receive an exclusive gift card offer and a chance to win $10,000* IRVINE, Calif. , July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21.",prnewswire.com,https://www.prnewswire.com/news-releases/allergan-aesthetics-celebrates-the-second-annual-juvederm-day-302209123.html,https://images.financialmodelingprep.com/news/allergan-aesthetics-celebrates-the-second-annual-juvderm-day-20240730.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-30 10:06:13,2024-07-30T10:06:13-04:00,2024-07-30,Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know,"Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2311694/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2311694,https://images.financialmodelingprep.com/news/investors-heavily-search-abbvie-inc-abbv-here-is-what-20240730.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-30 11:20:27,2024-07-30T11:20:27-04:00,2024-07-30,5 Dividend Aristocrats May Be Primed for a Big August,24/7 Insights Dividend Aristocrat shareholders could see some big upside in August.,247wallst.com,https://247wallst.com/investing/2024/07/30/5-dividend-aristocrats-may-be-primed-for-a-big-august/,https://images.financialmodelingprep.com/news/5-dividend-aristocrats-may-be-primed-for-a-big-20240730.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-30 12:17:30,2024-07-30T12:17:30-04:00,2024-07-30,AbbVie Analysts Lead the Stock Higher as Humira Worries Recede,"AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader range of treatments has more than paid off.",marketbeat.com,https://www.marketbeat.com/stock-ideas/abbvie-analysts-lead-the-stock-higher-as-humira-worries-recede/,https://images.financialmodelingprep.com/news/abbvie-analysts-lead-the-stock-higher-as-humira-worries-20240730.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-31 06:15:00,2024-07-31T06:15:00-04:00,2024-07-31,3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle,"Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate.",investorplace.com,https://investorplace.com/2024/07/3-powerhouse-growth-stocks-to-load-up-on-during-this-bull-market-cycle/,https://images.financialmodelingprep.com/news/3-powerhouse-growth-stocks-to-load-up-on-during-20240731.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-31 06:22:00,2024-07-31T06:22:00-04:00,2024-07-31,7 Stocks Set for a Major Bull Run,"Understanding companies' fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages.",investorplace.com,https://investorplace.com/2024/07/7-stocks-set-for-a-major-bull-run/,https://images.financialmodelingprep.com/news/7-stocks-set-for-a-major-bull-run-20240731.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-07-31 09:00:00,2024-07-31T09:00:00-04:00,2024-07-31,2 Stocks With Potential To Become Great Long-Term Investments,"Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to be a great long-term investment. Kenvue and Sila Realty Trust are two newly-listed companies that could potentially reward investors similarly to AbbVie.",seekingalpha.com,https://seekingalpha.com/article/4707628-2-stocks-with-potential-to-become-great-long-term-investments,https://images.financialmodelingprep.com/news/2-stocks-with-potential-to-become-great-longterm-investments-20240731.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-01 08:23:00,2024-08-01T08:23:00-04:00,2024-08-01,AbbVie Completes Acquisition of Cerevel Therapeutics,"Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 NORTH CHICAGO, Ill. , Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-cerevel-therapeutics-302212336.html,https://images.financialmodelingprep.com/news/abbvie-completes-acquisition-of-cerevel-therapeutics-20240801.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-01 12:46:46,2024-08-01T12:46:46-04:00,2024-08-01,"Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?","Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.",zacks.com,https://www.zacks.com/stock/news/2314470/should-you-buy-abbvie-abbv-after-q2-beat-guidance-raise?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2314470,https://images.financialmodelingprep.com/news/should-you-buy-abbvie-abbv-after-q2-beat-guidance-20240801.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-04 07:30:00,2024-08-04T07:30:00-04:00,2024-08-04,High-Yield Harvest: 3 Of My Favorite Dividend Stocks For What's Next,"The tech rally is losing steam as economic indicators, including rising unemployment and weak manufacturing data, suggest increasing recession risks. Investors are shifting focus from high-growth tech to value stocks, driven by concerns over valuation and a slowing economic outlook. In this uncertain environment, finding quality investments with solid balance sheets and growth potential is key to navigating potential market turbulence.",seekingalpha.com,https://seekingalpha.com/article/4710088-high-yield-harvest-3-of-my-favorite-dividend-stocks-for-whats-next-abbv-am-cme,https://images.financialmodelingprep.com/news/highyield-harvest-3-of-my-favorite-dividend-stocks-for-20240804.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-05 05:56:00,2024-08-05T05:56:00-04:00,2024-08-05,Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.,"The S&P 500 index came close to correction territory on Aug. 2, after falling about 5.7% from a peak it reached in mid-July. With drugs that some of us can't live without, Bristol Myers Squibb hasn't lowered its dividend payment in 25 years.",fool.com,https://www.fool.com/investing/2024/08/05/worried-about-a-market-correction-2-high-yield-div/,https://images.financialmodelingprep.com/news/worried-about-a-market-correction-2-highyield-dividend-stocks-20240805.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-05 11:55:25,2024-08-05T11:55:25-04:00,2024-08-05,"How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?","AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.",zacks.com,https://www.zacks.com/stock/news/2316191/how-should-you-play-astrazeneca-abbv-after-q2-beat-view-raise?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2316191,https://images.financialmodelingprep.com/news/how-should-you-play-astrazeneca-abbv-after-q2-beat-20240805.jpg
ABBV,2024-07-25,2024-07-18,2024-08-08,ABBV,,2024-08-08 14:05:17,2024-08-08T14:05:17-04:00,2024-08-08,3 Passive Income Dividend Stocks To Buy Now,Seasoned investors tend to closely follow the ups and downs of the market.,247wallst.com,https://247wallst.com/investing/2024/08/08/3-passive-income-dividend-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/3-passive-income-dividend-stocks-to-buy-now-20240808.jpg
